Abstract
After a first decade of using recombinant versions of natural proteins, novel engineered biologics have complemented the arsenal of medicine during the last 20 years. Today, tailor-made hormones, enzymes and fusion proteins offer optimised pharmacokinetic properties and new modes of action. Beside human(ized) antibodies, engineered protein scaffolds have recently entered the pharmaceutical R&D pipeline and open prospects for the specific targeting of diverse disease targets especially in the areas of oncology and inflammation.
| Translated title of the contribution | Recombinant therapeutic proteins - A success story |
|---|---|
| Original language | English |
| Pages (from-to) | 36-38 |
| Number of pages | 3 |
| Journal | BioSpektrum |
| Volume | 21 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 2015 |
